Summary We have previously demonstrated that amiodarone is able to reverse resistance of rat colon cancer cells to anthracyclines. We now compare the efficiency of amiodarone to verapamil one, another antiarrhythmic agent used in experimental systems and in clinical trials to enhance the effects of anthracyclines on resistant cancer cells. Amiodarone is more efficient than verapamil when both drugs are used at the same molar concentrations. Desethylamiodarone, the main metabolite of amiodarone, is as efficient as its precursor. Optimal concentrations of amiodarone are obtained without side effects in the sera of patients treated by oral administration followed by a loading infusion of amiodarone. On the other hand, maximal tolerated levels of verapamil reported in clinical trials are less efficient than amiodarone maximal levels in the reversal of resistance to anthracyclines in our experimental model in vitro. We suggest that amiodarone, which is more efficient and less toxic than verapamil, could be substituted for verapamil in future clinical trials.
In many experimental tumours, including rat colon cancer, resistance to anthracyclines is partly attributed to an energydependent efflux of the drugs from the cancer cells (Skovsgaard, 1975; Inaba et al., 1979) . Tsuruo et al. (1982) first demonstrated that verapamil was able to inhibit this efflux, so restoring sensitivity to anthracyclines of resistant cancer cells. We previously reported that amiodarone, a relatively non toxic antiarrhythmic agent, was able to restore sensitivity to anthracyclines in naturally resistant rat colon cancer cells (Chauffert et al., 1986) . In the present study, we demonstrate that amiodarone is more efficient than verapamil in enhancing the cytotoxic effect of 4'-deoxydoxorubicin on rat colon cancer cells. We also demonstrate that the effect of amiodarone on cancer cells is long-lasting and that efficient plasma concentrations of amiodarone can be reached in cancer patients without appreciable toxicity.
Materials and methods
Cells and culture conditions DHD/K12/PRO cell line was established in our laboratory from a transplantable colon adenocarcinoma induced by 1,2-dimethylhydrazine in syngeneic BDIX rats (Martin et al., 1975) . DHD/K12/PRO cells exhibit a primary resistance to anthracyclines due to an active drug efflux (Chauffert et al., 1984 (Milan, Italy) . DeoDXR was selected for this study due to its greater cytotoxicity for colon cancer cells compared to doxorubicin (Chauffert et al., 1986 Patient sera and amiodarone determinations Sera were obtained from 3 patients included in a clinical trial associating amiodarone and anthracyclines for the treatment of advanced colorectal cancer. Blood samples were collected after a period of at least 15 days during which the patients received an oral administration of 400mg amiodarone daily. The samples were collected before and at the end of a 3 h infusion of 450mg amiodarone diluted in 250ml of 50gl-1 dextrose solution. Concentrations of amiodarone and its main metabolite, desethylamiodarone, were determined according to Pourbaix et al. (1985) . Briefly, serum was extracted twice in a mixture of phosphate buffer (pH 5.4) and n-hexane in the presence of L 8040 as internal standard. The organic layer was dried then reconstituted in 200,ul ethanol; aliquots of this solution were injected in an HPLC system. The stationary phase was a lichrosorb CN 5 jm column and the mobile phase, an isocratic mixture of hexane, isopropylic alcohol and sulfuric acid (59.98; 39.98; 0.04). Drugs were detected at 242 nm with a UV detector. In one patient a sample of serum collected at the end of amiodarone infusion was also used to assay its enhancing effect on deoDXR-induced toxicity on rat colon cancer cells in culture. Normal human serum and serum of the amiodarone-treated patient were supplemented with 4,M deoDXR and assayed on tumour target cells as described above.
Quantitation of drug etfects Studies of [3H]thymidine incorporation were performed by a previous method (Chauffert et al., 1986 Another assay to determine the cytotoxic effect of drugs or their association was used, according to a previously described colorimetric test (Martin et al., 1982 Serum levels of amiodarone (Amiod.) and desethylamiodarone (Deamiod.) were compared after oral treatment for 15 days at least with amiodarone (400mgday-1) and before or after i.v. loading (450 mg) for 3 h. in reversing the resistance of rat colon cancer cells to deoDXR. We also find that desethylamiodarone, the main metabolite of amiodarone, is as efficient as its precursor. Furthermore, differing from verapamil, amiodarone induces a lasting effect on target cells which remains more sensitive to deoDXR even after extensive washing of amiodarone; this property of amiodarone is interesting in vitro but not necessarily in vivo because drug modifiers are usually administered simultaneously in therapy. We observe in three patients that serum levels of amiodarone plus desethylamiodarone are above 3,M after oral administration and reach at least 5.5 pM after intravenous amiodarone loading; clinical cardiovascular symptoms -changes in blood pressure or electrocardiographic record -were never observed in these 3 patients during admiodarone administration. Elevated serum concentrations have also been reported in patients treated by amiodarone for cardiac arrhythmias. Andreasen et al. (1981) obtained a mean plasma concentration of 1.7,M after daily oral administration of 200 mg, reaching 14.6 pM after an i.v. injection of 400 mg. Mostow et al. (1984) reported that serum concentration averaged 6.4 pM during the loading phase of an i.v. infusion at the rate of 120mg h -1 amiodarone. These clinically achievable concentrations are sufficient to obtain a maximal enhancing effect on anthracycline cytotoxicity in vitro.
Establishment of elevated serum levels of verapamil is much more limited by the cardiovascular effects of the drug -atrioventricular conduction block and arterial hypotension (Singh et al., 1978) . Reiter et al. (1982) reported a mean plasma concentration of 0.27 MM in a sustained intravenous infusion regimen in cardiac patients. In a clinical trial using infusion of verapamil for enhancing anticancer drug activity, the reported mean verapamil concentration was 0.62,M (Benson et al., 1985) . However, Rogan et al. (1984) reported verapamil levels above 3MM, in spite of cardiac cytotoxicity, in a clinical trial of verapamil-doxorubicin association against resistant ovarian cancers; at this concentration the maximum efficacy of verapamil is reached in our in vitro assay; however, at this concentration, verapamil is less efficient than amiodarone. Several other phase I trials are on-going with the goal of enhancing anthracycline efficacy by verapamil (Benson et al., 1985; Cantwell et al., 1985; Presant et al., 1984) . As amiodarone seems to be less toxic and a more efficient drug than verapamil in enhancing the effects of anthracyclines, we suggest that amiodarone, which reaches efficient plasma concentrations, could be substituted for verapamil in future clinical trials. However, toxic effects of amiodarone other than acute cardiac effects, have to be taken into account. Amiodarone may induce hyperthyroidism, peripheral neuropathy, interstitial pneumonia or hepatitis in a minority of treated patients (Lubbe et al., 1982) .
The mechanism of the enhancement of anthracycline cytotoxicity by amiodarone is likely to be, as in the case of verapamil, the inhibition of a drug efflux from cancer cells (Chauffert et al., 1986 ); however we have also observed that penetration of drug was of major importance in anthracycline toxicity. So, we used deoxydoxorubicin rather than doxorubicin due to its better penetration in colon cancer cells, especially at confluence. The purpose of our further investigations on resistance to anthracyclines will consider the both mechanisms; increased efflux and reduced penetration. It will be necessary to study the efficiency of amiodarone to reverse anthracycline resistance in other experimental tumour models, including human tumour cell lines or xenografts in nude mice.
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